| Execution period | April 1, 2026 to July 9, 2026 |
|---|
BSE filing, NSE: AARTIDRUGS. Summary written from the filing by ALFA Finder's alert engine.
Aarti Drugs Ltd: key numbers
- Share price
- ₹449.00
- Market cap
- ₹4,098 Cr
- Revenue (annual)
- ₹2,565 Cr
- Net profit (annual)
- ₹194.9 Cr
- P/E (TTM)
- 21.4×Sector 48.7×
- Promoter holding
- 54.07%-0.36% QoQ
- FII holding
- 2.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarti Drugs Ltd
All →Aarti Drugs Board Meeting Date
Aarti Drugs Ltd intimated BSE and NSE of a board meeting on November 3, 2026, to consider audited financial results for the quarter and half year ended September 30, 2026. Trading window remains closed until 48 hours after results declaration.
Aarti Drugs Other Announcement
The company submitted its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI Listing Regulations.
Aarti Drugs Other Announcement
Aarti Drugs has updated its list of authorized personnel for determining materiality of events and making stock exchange disclosures, effective October 1, 2026.
Aarti Drugs Management Change
Aarti Drugs Ltd announced the retirement of Director Uday M. Patil and the appointment of new directors, including Adhish P. Patil as the Managing Director.
Aarti Drugs Investor Presentation: Key Takeaways
Aarti Drugs reports Q1 FY27 revenue of ₹704 Cr, up 19% YoY. Management focuses on scaling regulated market sales through high-margin formulations and oncology backward integration.
Aarti Drugs Annual General Meeting
Aarti Drugs Limited conducted its 41st Annual General Meeting on September 26, 2026, to consider various ordinary and special business resolutions.
Other other announcement announcements
All →Lumino Industries Other Announcement
Lumino Industries intimated that its CIN and MCA listing status were updated after its BSE/NSE listing. This is a routine administrative compliance filing with no financial impact.
Aplab Other Announcement
Aplab confirmed zero deviation in utilizing its ₹6.29 Crore rights issue proceeds for Q3 FY27. This is a routine quarterly compliance certificate under SEBI ICDR.
Sathlokhar Synergys E&C Global Other Announcement
Sathlokhar Synergys filed its Q2 FY27 Reg 32 statement confirming no deviation in utilization of preferential issue proceeds. The company utilized ₹737.70 Cr of ₹932.36 Cr received, with no variation from stated objects.
Vardhman Special Steels Other Announcement
Vardhman Special Steels filed the Crisil Monitoring Agency Report for the quarter ended 30 September 2026. It reports no deviation from the preferential issue's use of proceeds.
Three M Paper Boards Other Announcement
Three M Paper Boards filed its Reg 13(3) investor grievance report. All complaint categories for the quarter show NIL figures.
Manika Plastech Other Announcement
Manika Plastech intimated a change in its CIN from U- to L-prefixed code following its September 2026 listing. This is a routine MCA registry update with no transactional or business substance.